Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tidutamab in advanced NET and GIST
NCT03411915Phase 1Completed
- Sponsor
- Xencor
- Start
- Jan 2018
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tidutamab in Neuroendocrine Neoplasm (NEN) and gastrointestinal stromal tumor (GIST), sponsored by Xencor. Primary endpoints: Safety and Tolerability Profile at 84 Days, Maximum Tolerated Dose and/or Recommended Dose at 84 Days and 3 more. Started Jan 2018; status: completed.
02
Drugs
tidutamab
03
Conditions
Neuroendocrine Neoplasm (NEN)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03411915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411915.